Glenn Goddard, EVP, Chief Financial Officer at Intellia Therapeutics, Inc. (NTLA), sold 31,200 shares at $153.22 ($5.0M) on 2021-08-30, disclosed to the SEC on 2021-09-01.
Open-market sale of $5.0M NTLA by EVP, Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $153.22 | 704 | $108K | 2.2% |
| 2 | $153.22 | 704 | $108K | 2.2% |
| 3 | $154.29 | 1,100 | $170K | 3.4% |
| 4 | $155.29 | 1,700 | $264K | 5.3% |
| 5 | $156.10 | 300 | $47K | 0.9% |
| 6 | $157.33 | 496 |
| $78K |
| 1.6% |
| 7 | $157.33 | 496 | $78K | 1.6% |
| 8 | $158.42 | 300 | $48K | 1.0% |
| 9 | $159.53 | 300 | $48K | 1.0% |
| 10 | $160.84 | 300 | $48K | 1.0% |
| 11 | $160.22 | 24,800 | $4.0M | 80.0% |
| Total | $159.28 avg | 31,200 | $5.0M | 100% |
| Filing → |
| NTLA | SELL | 2022-03-03 | $227K | — | Filing → |
| NTLA | SELL | 2021-09-09 | $1.3M | — | Filing → |
| NTLA | SELL | 2021-08-06 | $6.0M | — | Filing → |